NEW YORK (GenomeWeb) – Agendia said today that it has received CE marking for its next-generation sequencing-based MammaPrint BluePrint kit for breast cancer recurrence risk testing and molecular subtyping, allowing the firm to commercialize the device in Europe.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.